Targeting surface protein antigen I/II of streptococcus mutans using novel AG12 antimicrobial peptide
International Journal of Drug Delivery Technology · 12.06.2026 · 16 (53s)
DOI: 10.25258/ijddt.16.53s.67 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 12.06.2026. Verfasst von Medha Rajiv Ranjan und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Streptococcus mutans is a facultatively anaerobic, Gram-positive coccus commonly present in the human oral cavity and plays a significant role in the development of dental caries. The antigen I/II protein is a cell wall-anchored adhesin that facilitates bacterial attachment to tooth surfaces and contributes to biofilm formation and disease progression. AG12 is a novel peptide named based on its amino acid composition, including alanine, arginine, valine, tryptophan, phenylalanine, serine, leucine, and glycine. Zebrafish larvae are widely used as an in vivo model due to their physiological similarity to humans and their suitability for studying infection, immunity, and toxicity responses. Aim of the study: The study aims in inhibiting the surface protein antigen I/II of Streptococcus mutans using AG12 novel peptide and analysing its effect in the living system. Materials and Methods: ToxinPred and PeptideRanker were used as computational tools to evaluate peptide toxicity and bioactivity potential. Physicochemical and structural characterization of the peptide was performed. Helical wheel analysis was conducted to determine the peptide's amphipathic and helical properties. Molecular docking was performed to evaluate peptide-protein binding interactions. Zebrafish larvae were used as a model organism to assess toxicity and biological safety.
Results
ToxinPred analysis confirmed that AG12 is non-toxic and safe for biological applications. PeptideRanker analysis produced a score of 0.79 (>0.5), indicating strong bioactive potential. Structural analysis revealed amphipathic properties with favorable hydrophilic and hydrophobic balance, enhancing interaction capability. Docking studies showed strong binding affinity (-133 kcal/mol) with antigen I/II protein. Zebrafish studies showed negligible toxicity for AG12 compared to amoxicillin.
Conclusion
The AG12 peptide demonstrated strong binding affinity, indicating its potential in preventing Streptococcus mutans adhesion and reducing dental caries.
Zitieren
APA
Ranjan, M. R., & S, B. G. (2026). Targeting surface protein antigen I/II of streptococcus mutans using novel AG12 antimicrobial peptide. International Journal of Drug Delivery Technology, 16(53s). https://doi.org/10.25258/ijddt.16.53s.67
Vancouver
Ranjan MR, S BG. Targeting surface protein antigen I/II of streptococcus mutans using novel AG12 antimicrobial peptide. International Journal of Drug Delivery Technology. 2026;16(53s). doi:10.25258/ijddt.16.53s.67
BibTeX
@article{Ranjan2026,
author = {Ranjan, Medha Rajiv and S, Balaji Ganesh},
title = {Targeting surface protein antigen I/II of streptococcus mutans using novel AG12 antimicrobial peptide},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {53s},
doi = {10.25258/ijddt.16.53s.67}
}
EUVIMED